Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144/A NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144/A: Filer Information

Filer CIK0001293789Filer CCCXXXXXXXPrevious Accession Number Of The Filing0001971857-24-000856Is this a LIVE or TEST Filing?IVE TESTSubmission Contact InformationIVE TEST

Name Phone E-Mail Address

144/A: Issuer Information

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

001-38410 555 LONG WHARF DRIVE NEW HAVEN CONNECTICUT 06511 203-643-8060 Steinhart Richard I

BioXcel Therapeutics, Inc.

Officer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Securities
Common	Merrill Lynch 500 Cummings Center Suite 1600 Beverly MA 01915	430	154.35	42748364	12/16/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Amount of Date of Date you Nature of Name of Is Date Nature of Class **Person from Securities** Acquired Acquisition this Donor Payment Payment *

	Transaction	Whom Acquired	a Acquired Acquir Gift?	red
Common	12/14/2024 Restricted Stock Units	BioXcel Therapeutics	205	12/16/2024 Cash
Common	12/15/2024 Restricted Stock Units	BioXcel Therapeutics	225	12/16/2024 Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Richard Steinhart 555 Long Wharf Drive New Haven CT 06511	Common	09/16/2024	356	245.60
Richard Steinhart 555 Long Wharf Drive New Haven CT 06511	Common	10/03/2024	7175	3946.59

144/A: Remarks and Signature

Remarks	Amendment to correct number of shares sold from 438 to 430
Date of Notice	12/16/2024
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/14/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Richard Steinhart

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)